production of a therapeutic DC vaccination series requires more than 10 9 monocytes. WBC elutriation to enrich monocytes also requires a minimum of 10 9 monocytes as starting population for DC cell culture. 3 Currently, WBC yields from Trima Accel LRSCs are insufficient for the production of a whole therapeutic DC vaccine series. With improved ex vivo monocyte expansion protocols, the required minimum cell yield for DC vaccines could decrease. Given the mean loss of 10 9 WBCs per plateletpheresis collection by the Trima Accel, a 24-apheresisprocedures-per-year donor could lose more than 2 ¥ 10 10 WBCs. In comparison, the same number of plateletpheresis procedures with the COBE Spectra LRSCs would remove only 3.2 ¥ 10 7 WBCs per donation or a total of 7.7 ¥ 10 8 WBCs for 24 collections per year. Strauss 4 reported high losses of lymphocytes per PLT donation with previous plateletpheresis methods. This observation of immediate and long-term decreases in donors' lymphocyte counts lead to limits on the frequency of plateletpheresis. The number of WBCs retained by Trima Accel LRSCs after plateletpheresis is considerably less than the calculated WBC loss of these earlier studies. Only 10.8 percent of the PLT donors of our study (4/37) had decreased WBC counts immediately after plateletpheresis. For 89 percent of donors there was an increase in the postdonation WBC count (Table 1). The difference between predonation and postdonation WBC counts was slightly higher (p = 0.32) for Trima Accel procedures. A possible reason for that observation could be WBC recruitment, which may be greater during increased WBC loss. 2 Rock and coworkers found only minimal changes of donor WBC counts after repeated plateletpheresis. 5 Reasons for the variable number of WBCs retained in the Trima Accel LRSCs should be subject to further investigation to get a better standardization of this new WBC product.